TOVX

Theriva is a pre-revenue, clinical-stage oncology company whose entire value rests on a single lead asset, VCN-01, an oncolytic adenovirus that has only reached Phase 2b (VIRAGE, pancreatic cancer) and Phase 1 elsewhere. There is no product, no revenue (SalesRevenueNet $0.00), and a FY2025 net loss of -$23.7M on -$16.7M of operating cash burn. The accumulated deficit is -$359M against just $15.4M of stockholders' equity, and ROE is -154%. This is a company that has consumed a third of a billion dollars and has yet to commercialize anything — the definition of binary, unknowable risk.

The filing itself flashes survival warnings. Management explicitly states cash extends only 'into the first quarter of 2027' and even then is 'only sufficient to run certain clinical trials,' conceding 'no assurances can be provided.' The September 2025 restructuring cut 32% of staff (seven employees) to save ~$1.8M annually, R&D was slashed 28.5% to $8.6M, and the company is out-licensing SYN-020 (Rasayana deal) and shopping SYN-004 — these are the moves of a company preserving cash to stay alive, not one scaling toward a launch. With only $13.1M of cash against a ~$17M annual burn, another financing is a near-certainty within a year.